Amikacin Sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Amikacin Sulfate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
128
Registered trials
28
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Amikacin Sulfate can convert its Small molecule drug profile and 30S subunit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Amikacin Sulfate (query alias: amikacin liposome) |
|---|---|
| Modality / target | Small molecule drug; 30S subunit; 30S subunit inhibitors |
| Highest global status | Approved |
| Originator | Hubei Huazhong Pharmaceutical Co. Ltd. |
| Active developers | Demo S.A. Pharmaceutical Industry, Southern XP IP Pty Ltd., Pureims BV |
The MCP disease footprint includes Bone and joint infections, Central Nervous System Infections, Intraabdominal Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07694700 | Phase 4 | Active, not recruiting | 100 | clinical cure at 72 hours |
| NCT07369336 | Phase 4 | Completed | 90 | Duration of invasive mechanical ventilation |
| NCT07485010 | Phase 2 | Not yet recruiting | 300 | The primary outcome of the Intervention Program is microbiological clearance of Mycobacterium abscessus (MABS) with good tolerance of the interventions. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Safety and Feasibility of Grocery-Sourced Sublingual Immunotherapy (SLIT) for Food Allergy (FA) in Clinical Practice for Children and Adults
Not Applicable; n=51; evaluation: Positive. Reported fields: Adverse Reaction(at home dosing) = 24.0 Pts
Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease
Not Applicable; n=43; evaluation: Positive. Reported fields: Adverse Event: TEAE = non-serious and did not result in substantial treatment discontinuation
Sublingual Immunotherapy in Children with Atopic Dermatitis: A Meta-Analysis of Randomized Controlled Trials
Not Applicable; n=840; evaluation: Positive. Reported fields: DLQI: MD = -0.56(95.0% CI, -1.67 to 0.55), P-Value = 0.32; DLQI: MD = -0.56(95.0% CI, -1.67 to 0.55), P-Value = 0.32
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Amikacin Sulfate addresses Bone and joint infections, Central Nervous System Infections, Intraabdominal Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-06-14 | taiba Middle East FZ LLC Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE® in the Countries of GCC (Kingdom of Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain). | Approved | Financial terms not disclosed |
| 2018-01-13 | Nektar Therapeutics entered into a co-development, license and co-promotion agreement (Bayer Agreement) with Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly called NKTR-061) for the treatment of gram-negative pneumonias. | Phase 3 | US$175.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Terminal-sterilized amikacin sulfate injection and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method of amikacin sulfate injection”. The milestone feed surfaced a patent-application signal described as “Amikacin sulfate injection and preparation method thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
